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Here, we show that IL-10 and Rag1 double knockoutmice spontaneously develop colitis with dominantM1mac-
rophage phenotype, suggesting that IL-10 regulates macrophage orientation in inﬂammation. We demonstrate
that IL-10 stimulation induced miR-146b expression, and that the expression of miR-146b was impaired in IL-
10 deﬁcient macrophages. Our data show that miR-146b targets IRF5, resulting in the regulation of macrophage
activation. Furthermore, miR-146b deﬁcient mice developed intestinal inﬂammation with enhanced M1macro-
phage polarization. Finally, miR-146b mimic treatment signiﬁcantly suppresses M1 macrophage activation and
ameliorates colitis development in vivo. Collectively, the results suggest that IL-10 dependent miR-146b plays
an important role in the modulation of M1 macrophage orientation.
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Colitis1. Introduction
Interleukin 10 (IL-10) is a strong anti-inﬂammatory cytokine whose
role was ﬁrst reported as IFN-γ suppressing factor acting on Th1 cells
(Moore et al., 2001). It has since been shown that IL-10 signals through
the IL-10 receptor (IL-10R), which is expressed on a variety of cells, es-
peciallymany types of immune origin (Moore et al., 2001; Spencer et al.,
1998; Tan et al., 1993). The IL-10R complex is composed of two different
chains (IL-10R1 and IL-10R2). Binding of IL-10 to the IL-10R activates
phosphorylation of the receptor associated Janus tyrosine kinases,
resulting in STAT3-mediated signal transduction (Weber-Nordt et al.,
1996; Wehinger et al., 1996). IL-10 also inhibit macrophage production
of IL-12 (Moore et al., 2001). Recently, we and other groups have dem-
onstrated that IL-10also suppresses Th17 cell differentiation (Franke et
al., 2008). IL-10-deﬁcient mice have been shown to spontaneously de-
velop intestinal inﬂammation characterized by discontinuous
transmural lesions affecting intestines, and by dysregulated production
of proinﬂammatory cytokines including IL-12, IL-23, IFN-γ and IL-
17(Berg et al., 1995; Kuhn et al., 1993). Several key features of theIL-
10−/− chronic intestinal inﬂammation model are strikingly similar to1630, Icahn School of Medicine
29-6574, United States.
. This is an open access article underhuman inﬂammatory bowel diseases.Many cell types, includingmacro-
phages, produce and respond to IL-10(Moore et al., 2001), but it is cur-
rently not understood precisely how IL-10 affects macrophage
polarization, or the molecular mechanisms by which IL-10 regulates
macrophage gene expressions in the development of inﬂammatory
diseases.
Macrophages are key regulators of both innate and adaptive immu-
nity, serving as essential actors for both inﬂammatory responses to
combat pathogen insult and tissue damage, as well healing responses
that help repair affected tissue (Akira et al., 2013; Mills, 2012; Mosser
and Edwards, 2008). Macrophages can be differentiated into classically
activated macrophages (M1) or alternatively activated macrophages
(M2) in response to certain microbial stimuli and/or cytokine signals
(Akira et al., 2013; Tugal et al., 2013). M1 macrophages are believed to
play an important role in the pathogenesis of various inﬂammatory dis-
eases (Cassetta et al., 2011; Fernandez-Velasco et al., 2014;Mills, 2012).
M1 macrophages produce numerous proinﬂammatory mediators such
as tumor necrosis factor α (TNFα), interleukin-12 and 23, nitric oxide
(NO), and other reactive oxygen species (ROS), which are required for
host defense against pathogens (Mosser and Edwards, 2008).In con-
trast, M2 macrophages secrete signiﬁcant amounts of IL-10 and poly-
amines, adapting immune responses to promote angiogenesis and
tissue remodeling (Biswas andMantovani, 2010). At the transcriptional
level, M1 and M2 macrophages are regulated through differentthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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rophage differentiation (Lu et al., 2015), while IRF4 is necessary for M2
macrophage differentiation (Krausgruber et al., 2011; Satoh et al.,
2010). While recent work has unveiled many of the regulatory targets
downstreamof these transcription factors, someof the upstream factors
that may modulate the expression or activity of these factors remains
unknown. In this paper, we explore the role of an IL-10 induced
microRNA as a post-transcriptional regulator of IRF5 expression.
MicroRNAs (miRs) are small (22–24 nt) non-coding RNA sequences
that primarily function by interacting with the 3′UTRs of gene tran-
scripts and suppressing their translation or driving their degradation
(Baumjohann and Ansel, 2013; Friedman et al., 2009; Rebane and
Akdis, 2013; Selbach et al., 2008). They are sequentially processed
from longer transcripts by the ribo-nuclease III (RNase III) enzymes
Drosha and Dicer, after which they exert their function by guiding the
Argonaute (AGO) protein-containing miRNA-induced silencing com-
plex (miRISC) to speciﬁc target mRNAs through complimentary pairing
(Bartel, 2009; Fabian et al., 2010). miRs are integral in regulating gene
expression in both innate and adaptive immune cells. Interestingly, re-
cent studies demonstrated that IL-10 regulates the expression of several
miRs, includingmiR187, miR-155, andmiR-146a/b (Curtale et al., 2013)
(McCoy et al., 2010). For instance, IL-10 can inhibit miR-155 expression
induced by TLRs, and promote expression of anti-inﬂammatory genes
(McCoy et al., 2010; O'Connell et al., 2009). Curtale et al. reported that
LPS induced expression of miR-146b via an IL-10-dependent loop and
showed that miR-146b plays an anti-inﬂammatory role in human
monocytes by direct targeting the TLR4 signaling pathway (Curtale et
al., 2013).Despite these studies, the roles played by the IL-10-miRs
axis in the control of macrophage orientation and inﬂammatory disease
development remained poorly deﬁned.
In the present study, we show that IL-10 and Rag1 double knockout
mice (IL-10−/−/Rag1−/−) spontaneously develop colitis with high
levels of M1 macrophage signature molecules, suggesting that IL-10
regulated M1 macrophages may contribute to the colitis development.
We demonstrate that IL-10 or LPS stimulation induced miR-146b ex-
pression in macrophages, and that the expression of miR-146b was im-
paired in IL-10 deﬁcient macrophages. Furthermore, RNA
immunoprecipitation assay showed that miR-146b and IRF5 could oc-
cupy the samemiRNA-induced silencing complex (miRISC). In addition,
miR-146b mimic signiﬁcantly decreased the IRF5 3′UTR activity and
IRF5 protein expression induced by LPS.miR-146b deﬁcientmice exhib-
it enhanced M1 macrophage polarization. Finally, treatment with miR-
146b mimic signiﬁcantly suppressed M1 macrophage activation and
ameliorated colitis development. Taken together, the results suggest
IL-10-miR-146b-IRF5 axis plays an important role in the modulation
of M1 macrophage activation and highlight the role of miR-146b in
the control of immune responses.
2. Materials and Methods
2.1. Mice
C57BL/6J (WT), IL-10 deﬁcient, IL-10R2 deﬁcient, and Rag1 deﬁcient
micewere obtained from Jackson laboratory andmaintained in the bar-
rier facility at the Icahn School of Medicine at Mount Sinai. IL-10/Rag1
double knockout animals were generated by crossbreeding the single
knockouts. All animal study protocolswere approved by the Institution-
al Animal Care and Use Committees of Icahn School of Medicine at
Mount Sinai.miR-146b deﬁcient mice was generated with CRISP/Cas9
by Applied Stem Cell.
2.2. Preparation of Bone Marrow Derived Macrophages
Bone marrow (BM) cells were isolated from tibias and femurs of
C57BL/6 mice following dissection by direct ﬂushing with PBS, and the
cells were cultured in the complete DMEM medium supplementedwith GM-CSF (10 ng/ml). On day 6 or 7, the resulting bone marrow de-
rived macrophages (BMDMs) were harvested and then seeded in fresh
complete DMEM medium at a density of 2 × 106 cells/ml for experi-
ments. Cells further treated with LPS and/or IFN-γ were considered as
M1 macrophages.
2.3. Intracellular Staining and Flow Cytometry
Bone marrow derived macrophages were either activated with LPS
(100 ng/ml) plus IFN-γ (20 ng/ml) or LPS alone at different concentra-
tion overnight, with brefeldin A added to the culture 5 h prior to har-
vesting. Cells were ﬁxed with IC Fixation Buffer (BD Bioscience),
incubated with permeabilization buffer, and consequently stained
with PE-anti-mouse IL-12 p40, APC-anti-iNOS and PE-Cy 5.5 anti-
mouse CD11b antibodies. For co-culture experiments, CD4, CD44, and
CD25 antibodies (all BD biosciences) were also used. Flow cytometry
was performed on a FACS (BD Biosciences) and captured data was sub-
sequently analyzed using FlowJo 7.0.
2.4. RNA Isolation and Quantitative Real-time RT–PCR (qPCR)
Total RNAwas extracted using anRNeasy plus kit (QIAGEN, Valencia,
CA) per the protocol provided, and cDNA was generated with an oligo
(dT) primer and the Superscript II system (Invitrogen, USA) followed
by analysis using iCycler PCRwith SYBRGreen PCRmasterMix (Applied
Biosystems). Results were normalized against the expression of
ubiquitin.
2.5. Transfection and Luciferase Reporter Assay
293T cells were transiently transfected with WT or mutant IRF5 3′
UTR luciferase reporter plasmid in the presence of miR-146b mimic at
different concentrations. For each transfection, 2.0 μg of plasmid was
mixedwith 100 μl of DMEM (without additives) and 4.0 μl of Lipofecta-
mine™ 2000 reagent. The mixture was incubated at room temperature
for 20 min per the protocol provided and added to 12-well plates con-
taining cells and complete medium. The cells were incubated for 30 h
and harvested using reporter lysis buffer (Promega) for determination
of luciferase activity. Cells were co-transfected with a β-galactosidase
reporter plasmid to normalize experiments for transfection efﬁciency.
2.6. T cell Proliferation Assay
CD4+ T cells were puriﬁed from spleens and lymph nodes of OTII
mice and the cells were labeled with CFSE. The labeled cells
(1 × 105/well) were co-cultured with macrophages in the absence or
presence of anti-CD3 (1 μg/ml) and anti-CD28 (2 μg/ml) antibodies for
three days in 96-well microplates. CFSE dilution assay was analyzed
using ﬂow cytometry.
2.7. Immunoblotting Analysis
Cellswerewashedwith cold phosphate-buffered saline and lysed for
15 min on ice in 0.5 ml of lysis buffer (50 mM Tris-HCl, pH 8.0, 280mM
NaCl, 0.5% Nonidet P-40, 0.2 mM EDTA, 2 mM EGTA, 10% glycerol, and
1 mM dithiothreitol) containing protease inhibitors. Cell lysates were
clariﬁed by centrifugation (4 °C, 15 min, 14,000 rpm) and protein was
run on 10% SDS-PAGE gels for immunoblotting. Anti-iNOS (Santa
Cruz), anti-IRF5 (MBL), anti-STAT1, and anti-β-actin (Sigma) antibodies
were used according to the manufacturer's instructions. Secondary
HRP-conjugated antibodies were from Santa Cruz.
2.8. Endotoxin-induced Model of Sepsis
Septic shock inmicewas induced by injecting 6mg/kg E. coli-derived
ultra-pure LPS or PBS i.p. Survival after injection was monitored and
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servation of a loss of self-righting and insensitivity to touch. A lower-
dose model was also applied, in which mice were injected i.p. with
LPS (300 μg/mouse) for 4 h and sera were collected as appropriate,
along with other key organs such as the spleen.2.9. Chromatin Immunoprecipitation (ChIP) Assay
ChIP was performed using an assay kit following themanufacturer's
instruction (Upstate Biotechnology, Lake Placid NY). Brieﬂy, activated
macrophages were cross-linked by exposure to 1% formaldehyde for
10 min at 37 °C.·Nuclei were prepared and subjected to sonication to
obtain DNA fragments. Chromatin fractions were precleared with pro-
tein A-agarose beads followed by immunoprecipitation overnight at
4 °C with 3 μg of anti-IRF5 (Santa Cruz) or control antibody. Cross-
linking was reversed at 65 °C for 4 h, before proteinase K digestion.
DNA was puriﬁed and subjected to qPCR. The input DNA was diluted
200 times prior to PCR ampliﬁcation. The input and
immunoprecipitated DNA were ampliﬁed by qPCR using primers
encompassing the known IRF5 binding sites on the IL-12 promoter
region.2.10. Cytokine ELISA
Supernatants from cell cultureswere collected after activation under
various conditions and secreted cytokines in the supernatants were
measured following appropriate dilution by ELISA kits with puriﬁed
coating and biotinylated detection antibodies: anti-IL-12 p40 (R & D
systems), and anti-IL-6, and anti-TNFα (BD Bioscience). All samples
were analyzed according to manufacturer instructions.2.11. Immunoprecipitation of Ago2-bound RNAs (RIP) Assay
Immunoprecipitation of Ago2-bound RNAs, which contains miRs
and their target mRNA, was performed as previously described
(Curtale et al., 2013). Brieﬂy, 3 × 106 BMDMs derived from C57BL/6
mice were stimulated with LPS (100 ng/ml) plus IFN-γ (20 ng/ml) for
4 h. An aliquot of immunoprecipitation supernatants, corresponding
to 0.5 × 106 cell equivalent, was removed after immunoprecipitation
as “input”. Results were expressed as fold enrichment relative to
Ago2-immunoprecipitation control samples.2.12. IHC and Immunoﬂuorescence
Sections were de-parafﬁnized in xylene and dehydrated in ethanol.
Primary antibody was incubated overnight at 4 °C and secondary bio-
tinylated antibody was detected with streptavidin-HRP or
-Fluorescent probe-conjugated antibody. Sections were development
using a DAB peroxidase substrate kit (BioGenex). For immunoﬂuores-
cence, media counting with DAPI was used. Images were acquired
using a Nikon Eclipse NE and with NIS elements BR software. Histolog-
ical score was evaluated as follows (Tomita et al., 2009 #149): submu-
cosa damage, 0; normal or widely scattered leukocytes, 1; focal
aggregates of leukocytes, 2; diffuse leukocyte inﬁltration with expan-
sion of submucosa, 3; diffuse leukocyte inﬁltration.2.13. Fluorescence In Situ Hybridization (FISH)
Double digoxin-labeled locked-nucleic acid (LNA) probes (Exiqon)
for miR146b were denatured by heating at 90 °C for 4 min then diluted
to 40 nM using in situ hybridization buffer (Exiqon). The sections were
hybridized with 50 μl of diluted probe at 58 °C for 1 h then washed in
decreasing SSC concentrations at hybridization temperature.2.14. miR-146b Mimic Administration
13-week old IL-10−/− mice were divided into two groups (6 mice/
per group): Treatment group and Control group. In the treatment
group, IL-10−/−micewere treatedwithmiR-146bmimic intraperitone-
ally twice a week with 10mg/kg; while in the control group, mice were
treatedwithmiR-146b scramble at same dose for 3weeks. Bodyweight
was monitored every week and mice were sacriﬁced 3 weeks later.
2.15. Model Simulation
We constructed a conceptual model consisting of an incoherent
feed-forward motif (Fig. S11A) that controls LPS induced M1 macro-
phage polarization. By using simple hill functions to capture both inhibi-
tion and activation relationships between modeling species (IRF5, IL10,
miR and IL12 to represent levels of IRF5, IL10, miR146b and IL12+M1
macrophage population), a set of ordinary differential equations (Eqs.
(1)–(4)) was built to describe the rates of changes. We posit that
IL12+M1macrophage population (IL12) was controlled by IRF5 as ev-
ident in Eq. (4). Table S1 listsmodel parameters,whichwere adjusted to
enable dynamic simulation of observed experimental data. XPPAUT 7.0
(http://www.math.pitt.edu/~bard/xpp/xpp.html) was used to perform
the simulation analyses. The .ode ﬁle used for simulation is provided
in Table S2.
dIRF5
dt
¼ g1∙ LPS
n1
km1n1 þ LPSn1
−
km2n2 þ k1∙miRn2
km2n2 þmiRn2
∙IRF5
 !
ð1Þ
dIL10
dt
¼ g2∙ k2∙LPS
n3
km3n3 þ LPSn3
−IL10
 !
ð2Þ
dmiR
dt
¼ g3∙ k3∙IL10
n4
km4n4 þ IL10n4
−miR
 !
ð3Þ
dIL12
dt
¼ g4∙ IRF5
n5
km5n5 þ IRF5n5
−IL12
 !
ð4Þ
2.16. Statistical Analysis
The results are shown as means ± s.d. and statistical analysis was
performed using Student's t-test. Where more than two groups were
compared, one way-ANOVA with Bonderroni's was performed;
Kaplan-Meier was used for survival analysis. P values b 0.05 were con-
sidered statistically signiﬁcant.
3. Results
3.1. IL-10 Regulates M1 Macrophage Polarization During Colitis
Development
Although it is well established that IL-10 and IL-10R2 deﬁcient mice
spontaneously develop intestinal inﬂammation, the molecular mecha-
nisms that cause the changes are still not clearly understood. As results,
we revisited the development of colitis in IL-10 and IL-10R2 deﬁcient
mice. As expected, IL-10 and IL-10R2 deﬁcient mice (13 to 16 weeks
of age) spontaneously develop colitis in our animal facility, and histo-
logical analysis showed that inﬂammatory cells were highly inﬁltrated
in the mucosal layers of colons in mice with colitis (Supplementary
Fig. 1A). Microarray experiments showed that mRNA expression of
M1macrophage signature genes were signiﬁcantly increased in intesti-
nal tissues of IL-10 deﬁcient mice with colitis compared with WT mice,
andGOanalysis showed that the activation ofmacrophage functionwas
enhanced in IL-10−/−mice (Supplementary Fig. 1B). qPCR experiments
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signiﬁcantly in IL-10 deﬁcient mice (Supplementary Fig. 1C). The levels
of IL-12/23p40, TNFα, and IL-6production were signiﬁcantly increased
in IL-10 deﬁcient mice compared with WT mice (Supplementary Fig.
1D). Immunohistological staining indicated that F4/80+iNOS+ cells
are clearly present in the mucosa of colon tissues of IL-10 deﬁcient
mice (Supplementary Fig. 1E). F4/80+cells and F4/80+IL-12/23 p40+
cells were present more in the LPMCs of IL-10−/− mice than WT (Sup-
plementary Fig. 1F).
To investigate further the role of IL-10 regulatedmacrophages in the
pathogenesis of colitis, we cross-bred IL-10−/− and Rag1−/− mice and
generated IL-10 and Rag1 double knockout mice (IL-10−/−/Rag1−/−).
Interestingly, IL-10−/−/Rag1−/−mice spontaneously developed colitis
at around 13 weeks of age in our animal facility, as shown by histology
and disease score of intestinal inﬂammation (Fig. 1A, B). qPCR analysis
showed that mRNA expression of M1 macrophage signature genes in-
cluding iNOS, IL-12/23 p40, IL-6, and TNFα signiﬁcantly increased in in-
testinal tissues of IL-10−/−/Rag1−/− comparedwith Rag1−/−mice (Fig.
1C). Immunohistological staining showed that iNOS positive F4/80+
cells were present in the mucosa of colons of IL-10−/−/Rag1−/− mice
(Fig. 1D). IL-12/23p40 and TNFα positive F4/80+ cellswere signiﬁcantlyFig. 1. IL-10 deﬁcient M1 macrophages drive colitis development. Rag−/− and Rag−/−/IL-10−
intestinal morphology and H&E staining of colon tissues (upper panel scale bar, 100 μm; low
10−/−mice (*p b 0.05). (C) The mRNA levels of TNFα, IL-12/23 p40, and IL-6 in the colon tissu
(D) Detection of iNOS-expressing F4/80 positive cells by immunoﬂuorescence in colon tissu
100 μm). (E, F) The presence of IL-12/23 p40-producing F4/80 positive cells in lamina propria
on F4/80+ cells and the percentages of IL-12/23 p40-producing cells shown (*p b 0.05; **p b
incubated with IFN-γ (20 ng/ml) plus LPS (100 ng/ml) for 24 h, stained for intracellular IL
CD11b+ cells and the percentage of IL-12/23 p40 positive cells are shown (**p b 0.01). (H) E
cytokines, as in (C). All the experiments were repeated three times with similar results.increased in the spleen (data not shown), andMHCII+F4/80+cells were
increased in the LPMCs of mucosa of colon in IL-10−/−/Rag1−/−mice
(Fig. 1E, F). Next, we prepared bone marrow-derived macrophages
from both Rag1−/− and IL-10−/−/Rag1−/− mice and activated the
cells with LPS (100 ng/ml) and IFN-γ (20 ng/ml) overnight for M1mac-
rophage activation and examined the percentage of IL-12p40-produc-
ing cells by intracellular staining using ﬂow cytometry. Notably, the
frequency of IL-12/23p40-producing cells derived from IL-10−/−/
Rag1−/− mice was signiﬁcantly greater than that of cells from
Rag1−/− mice (Fig. 1G). Furthermore, the production of TNFα, IL-6
and IL-12/23 p40 was signiﬁcantly increased in the serum of IL-10−/−/
Rag1−/−mice (Fig. 1H), suggesting that the increases in cell population
had manifest M1 phenotype. Overall, the results suggest that macro-
phages are strongly skewed towards strong M1 type in IL-10−/−/
Rag1−/− mice.
3.2. IL-10 Deﬁciency Enhances M1 Macrophage Polarization
To investigate further the function of IL-10 in macrophage differen-
tiation, we assessed the characteristics of macrophage development in
IL-10-deﬁcient mice. Bone marrow cells from IL-10−/− or WT control/− mice were raised until 20 weeks of age and mice were sacriﬁced. (A) Photographs of
panel scale bar, 50 μm); (B) disease score in the colon tissues of Rag−/− and Rag−/−/IL-
e of the WT, IL-10−/− and IL-10R2−/− mice (n = 5) (*p b 0.05; **p b 0.01; ***p b 0.001).
e of Rag−/− and Rag−/−/IL-10−/− mice (red, F4/80; green, iNOS; blue, DAPI, scale bar,
portion of Rag−/− and Rag−/−/IL-10−/− mice, with representative FACS dot plots gated
0.01; ***p b 0.001). (G) BMDMs cultured from Rag−/− and Rag−/−/IL-10−/− mice were
-12/23 p40, and analyzed by ﬂow cytometry. Representative FACS dot plots gated on
LISA of the serum of the mice detecting the expression of several key pro-inﬂammatory
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then performed microarray experiment to examine M1 macrophage
signature gene expression at various timepoints (0, 2, 4, 8 h). As expect-
ed, the mRNA expression of all theM1macrophage signature genes, in-
cluding IL-6, IL-12B, Nos2, and CXCL2, was signiﬁcantly increased in IL-
10−/− macrophages compared to that of WT cells (Fig. 2A). These re-
sults were conﬁrmed via qPCR experiments (Fig. 2B). Flow cytometry
analysis showed that the percentages of these M1 signature molecule-
expressing cells signiﬁcantly increased in IL-10 deﬁcient cell cultures
comparedwithWT control cells (Fig. 2C, data now shown).These obser-
vations also correlated with the enhanced secretion of IL-12p40, IL-6,
and TNFα by IL-10−/− M1 macrophages as determined by ELISA (Fig.
2D). To exclude the possibility that the enhanced M1 macrophage dif-
ferentiation was due to abnormal myeloid cell development, we exam-
ined myeloid cell population from bone marrows and lymph nodes of
WT and IL-10−/−mice (Supplementary Fig. 2A), and veriﬁed that mye-
loid cells develop normally in IL-10−/− mice. In addition, we analyzed
whether IL-10 signaling cascade affects M1macrophage differentiation.
Similar to IL-10 deﬁcient mice, IL-10R2 deﬁcient mice exhibited en-
hancedM1macrophage activation (Supplementary Fig. 2B). The results
suggest that IL-10-IL-10R2 signaling cascade plays a negative role inM1
macrophage differentiation.Fig. 2. IL-10 deﬁciency promotes M1 macrophage differentiation. (A) BMDMs from wild type o
time points (0, 2, 4, 8 h) and mRNAwas isolated for microarray analysis. Snapshots from heat m
the same areas of all six heat maps, with 6 loci of interest being highlighted. (B) BMDMs treat
macrophage gene expression (data represent mean ± s.d.). (C). The cells prepared in A were
cytometry. Representative FACS dot plots gated on CD11b+ cells and the percentages of IL
prepared in (A) were stimulated with IFN-γ (20 ng/ml) plus LPS (100 ng/ml) for 24 h and th
ELISA. *p b 0.05; **p b 0.01. The results are representative of three independent experiments.Since M1 macrophages are known to also be inﬂuential on adaptive
immune responses, we then sought to investigate how IL-10−/−macro-
phages regulate T cell activation.We ﬁrst analyzed expression ofMHC II
and other co-stimulatory factors in IL-10 deﬁcient macrophages. Bone
marrow cells from WT and IL-10−/− mice were activated as before
with LPS (100 ng/ml) plus IFN-γ (20 ng/ml) towards M1 macrophage
differentiation. The results showed that the percentages of MHC II and
CD86 positive cells were signiﬁcantly higher in IL-10 deﬁcient mice
(Supplementary Fig. 3A). Next, we co-cultured WT or IL-10−/−macro-
phages with OTII CD4+ T cells, and observed that activation markers
including CD25 and CD44were signiﬁcantly increased in OTII CD4+ T
cells co-cultured with IL-10−/− macrophages (Supplementary
Fig. 3B). In addition, IFN-γ-producing CD4+ T cells was signiﬁcantly
increased in cultures with IL-10 deﬁcient macrophages (Supplemen-
tary Fig. 3C). Taken together, the results indicate that IL-10 deﬁcient
macrophages induce stronger T cell activation, consistent with a M1
phenotype.
3.3. miR-146b Induced by IL-10 Suppresses M1 Macrophage Polarization
Since several recent studies have identiﬁed that IL-10 can regulate
the expression of a few miRs including miR-187, miR-155, miR-146a,r IL-10−/−mice were stimulated with IFN-γ (20 ng/ml) plus LPS (100 ng/ml) for various
aps show 72 genes related to macrophage activation. The position of each gene locus is in
ed as in (A) for 4 h. Total RNA was prepared and qPCR was performed for the analysis of
stimulated with IFN-γ (20 ng/ml) plus LPS (100 ng/ml) overnight and analyzed by ﬂow
-12p/23 p40-producing and iNOS-expressing CD11b+ cells are shown. (D). The cells
e supernatants were analyzed for the level of IL-12/23 p40, TNFα and IL-6 production by
88 L. Peng et al. / EBioMedicine 14 (2016) 83–96andmiR-146b,we explored the possibility of thosemiRs contributing to
the phenotype observed. To investigate the contribution of miRs exclu-
sively dependent on IL-10 duringmacrophage polarization, we ﬁrst an-
alyzed the expression of several previously suggested candidates of
interest in WT and IL-10−/− macrophages stimulated with IFN-γ/LPS.
The qPCR results showed WT macrophages activated with IFN-γ/LPS
did express, miR-155, miR-146a, and miR-146b; however, the expres-
sion of miR-146b was the most strikingly impaired in IL-10−/− mice
(Supplementary Fig. 4A). The impaired miR-146b expression was con-
ﬁrmed by in situ hybridization (Supplementary Fig. 4B). Thus we fo-
cused on miR-146b in the investigation of IL-10 regulation of M1
macrophage polarization. To understand whether miR-146b can affect
the M1 macrophage differentiation, bone-marrow-derived macro-
phages from WT and IL-10−/− mice were transfected with miR-146b
mimic. Two days later, the cells were activated with IFN-γ/LPSFig. 3.miR-146b suppressesM1macrophage activation by targeting IRF5. (A) Schematic represe
predictedmiR-146b binding region is indicated (left panel). HEK293T cellswere co-transfectedw
30 h. The cell lysates were prepared and luciferase activity was detected (Data represent mean
(100 ng/ml) for 4 h. Total RNA was extracted and immunoprecipitated with anti-Ago2 antibo
of miR-146b and IRF5 mRNA expression (Data represent mean ± s.d.). (C) BMDMs from C57
(B) for 24 h. The whole cell lysates were prepared and western blotting was performed for th
mice were transfected with miR-146b mimic (3 μM) or scramble (3 μM) and stimulated as in
DNA with primers ﬂanking the IRF5 binding site in the IL-12 promoter region. (E) Western blo
or 48 h. (F) BMDMs as prepared in A were transfected with either IRF5 siRNA or control siR
intracellular IL-12/23 p40 and analyzed by ﬂow cytometry. Representative FACS dot plots gate
(G) BMDMs prepared in A were transfected with IRF5 siRNA or control siRNA and the c
supernatants were collected and the level of IL-12 p40, TNFα and IL-6 production in the supe
at least two independent experiments.overnight. The results showed that the percentage of IL-12/23 p40-pro-
ducing cells was signiﬁcantly decreased in cultures treated with miR-
146b compared with control cultures (Supplementary Fig. 4C). Similar-
ly, the release of cytokines including IL-12 p40, IL-6, and TNFα in the
culture supernatants was signiﬁcantly reduced when analyzed by
ELISA (Supplementary Fig. 4D).These results suggest that miR-146b is
induced and involved in the activation of M1 macrophages and may
modulate M1 macrophage differentiation.
3.4. miR-146b Targets IRF5 in the Regulation of M1 Macrophage
Polarization
IRF5 has been deﬁned as a key transcription factor for M1 macro-
phage differentiation. Bioinformatics analysis revealed that human
IRF5 is one of the predicted targets of miR-146b (data not shown).ntation of wild-type (wt) andmutant (mut) IRF5 3′UTR luciferase reporter constructs. The
ith eitherWTormutant IRF5 luciferase reporter plasmids together themiR-146mimic for
± s.d.). (B) BMDMs from C57BL/6 mice were stimulated with IFN-γ (20 ng/ml) and LPS
dy. The immunoprecipitated RNA was puriﬁed and qPCR was performed for the analysis
BL/6 mice were transfected with miR-146b mimic (3 μM) for 48 h and stimulated as in
e analysis of IRF5 expression, using GAPDH expression as a control. (D) BMDMs fromWT
B,C for 4 h, followed by ChIP assay. PCR was used to quantify the amount of precipitated
t of whole cell lysates from BMDMs of WT and IL-10−/−mice stimulated as before for 24
NA for 48 h and subsequently stimulated as before for 24 h. The cells were stained for
d on CD11b+ cells and the percentage of IL-12/23 p40-producing CD11b+ cells is shown.
ells were then stimulated with IFN-γ (20 ng/ml) and LPS (100 ng/ml) for 24 h. The
rnatants was analyzed for by ELISA. *p b 0.05; **p b 0.01. All results are representative of
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3A left).To verify ifmiR-146b really targets IRF5, we constructed lucifer-
ase reporter plasmids of the IRF5 3′UTR ofmice (includingWT andmiR-
146b binding site mutant copies). The plasmids were then respectively
co-transfected with the miR-146b mimic to HEK293T cells. Interesting-
ly, transfection ofmiR-146bmimic signiﬁcantly decreased the luciferase
activity in cells transfected with IRF5 plasmid; however, miR-146b
mimic had no effect on luciferase activity in cells transfected with IRF5
mutant plasmid (Fig. 3A right). RNA immunoprecipitation (RIP) exper-
iments demonstrated that the miR-146b and IRF5 mRNA were in the
same miRNA-induced silencing complex (miRISC) (Fig. 3B). This inter-
action was then evaluated at the protein level, where we found that
miR-146b mimic suppressed IRF5 protein expression in IFN-γ/LPS-in-
duced M1 macrophages (Fig. 3C). SinceIRF5 is known to be a key regu-
lator of IL-12 p40, the regulation of IL-12 p40 in the presence ofmiR-
146b mimic by ChIP (Fig. 3D). We ﬁrst examined if IRF5 plays a role in
enhanced M1 macrophage differentiation in IL-10−/− mice. Per expec-
tation, IRF5 protein is more stable in IL-10−/− macrophages over time
as compared to WT cells (Fig. 3E). Knockdown of IRF5 by siRNA signiﬁ-
cantly reduced the percentage of IL-12p40-producing cells and cytokine
release (Fig. 3F, G).The results indicate that IRF5 is indeed involved in
the enhanced M1 macrophage differentiation in IL-10−/− mice. To fur-
ther conﬁrm that miR-146b targets IRF5 resulting in the regulation of
M1 macrophage activation, miR-146b mimic treated macrophages
were overexpressed with IRF5 or control plasmid, overexpression of
IRF5 rescued miR-146b mimic-induced suppression of M1 macrophage
activation and signiﬁcantly enhanced CD4+ T cell activation (Fig. 4A, B,Fig. 4. Overexpression of IRF5 rescued miR-146b mimic-induced suppression of M1 macroph
(3 μM), miR-nc and IRF5 overexpression plasmid for 48 h and the cells were then stimulated
expression. (B) BMDMs from C57BL/6 mice were prepared under the same conditions as in A.
the supernatants was analyzed for by ELISA. ***p b 0.001. (C) BMDMs from C57BL/6 mice tre
Representative FACS dot plots gated on CD11b+ cells and the percentage of IL-12/23 p40-p
nodes of OTII mice were prepared and the cells were incubated with IL-10−/− BMDMs (un
(3 μM), miR-nc and IRF5 overexpression plasmid for three days. The cells were stained for int
CD4+ cells and the percentages of IFN-γ-producing CD4+ cells are shown. (E) The supernata
were repeated three times with similar results.C, D, E). Thus, the results suggest IL-10-induced miR-146b modulates
M1 macrophage differentiation by targeting IRF5.
3.5. miR-146b Deﬁciency Enhanced M1 Macrophage Orientation
To further analyze the function of miR-146b in the control of macro-
phage orientation, we generated miR-146b deﬁcient mice by CRISPR/
Cas9 (Supplementary Fig. 5A, B, C). Mir146b−/−mice displayed en-
larged spleens and increasedmyeloid cell population and spontaneous-
ly developed intestinal inﬂammation (Fig. 5A, B, C, D; Supplementary
Fig. 5D). BMDMs polarized towards M1 inmiR-146b deﬁcient cell cul-
tures showed elevated percentages of IL-12p40+ cells compared with
WT controls (Fig. 5E). These observations correlated with enhanced se-
cretion of IL-12p40, IL-6, and TNFα by mir146b−/−M1macrophages as
determined by ELISA (Fig. 5F). In addition, western blot experiments
showed that IRF5 protein expression was signiﬁcantly enhanced
inmiR-146b−/− macrophages compared to that of WT cells (Fig. 5G).
Furthermore, miR-146b mimic signiﬁcantly suppressed the expression
of M1 macrophage signature genes in Mir146b−/− macrophages (Fig.
5H, I, J). However, IL-10 lost its suppressing effects on M1 macrophage
activation in Mir146b−/−macrophages (Fig. 5K, L). These results con-
ﬁrmed that miR-146b is critically involved in M1 macrophage
polarization.
Having observed that mir146b−/−macrophages behaved in a man-
ner consistent with an enhanced M1 proﬁle, we then sought to investi-
gate how they regulate T cell activation using co-cultured WT or
Mir146b−/−macrophages with OTII CD4+ T cells. The results showedage activation. (A) BMDMs from IL-10−/− mice were transfected with miR-146b mimic
with IFN-γ (20 ng/ml) and LPS (100 ng/ml) for 24 h prior to western blotting for IRF5
The supernatants were collected and the level of IL-12 p40, IL-6, and TNFα production in
ated as in B were stained for intracellular IL-12/23 p40 and analyzed by ﬂow cytometry.
roducing CD11b+ cells is shown (*p b 0.05). (D) CD4+ T cells from spleens and lymph
stimulated or stimulated with IFN-γ and LPS) with cotransfection of miR-146b mimic
racellular IFN-γ and analyzed by ﬂow cytometry. Representative FACS dot plots gated on
nts in (D) were analyzed for IFN-γ production by ELISA. **p b 0.01. All the experiments
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CD4+ T cell activation (Fig. 6A, B). CFSE dilution assay showed that
there was stronger T cell proliferation in cells co-cultured with
Mir146b−/−macrophages compared with WT macrophages (Fig. 6C).
However, Mir146b−/−macrophages treated with miR-146b mimic re-
sulted in signiﬁcantly reduced activation of CD4+ T cell activation (Fig.
6D, E). In addition, Mir146b−/−macrophages were less responsive to
IL-10-induced suppression of T cell activation as seen in WT macro-
phages (Fig. 6F, G). Taken together, the results indicate that miR-146b
deﬁcient macrophages induce strong T cell activation.3.6. Treatment With miR-146b Mimic Ameliorated Colitis Development
Given our results demonstrating the important function of miR-146
in control of gene transcriptional program in M1 macrophage differen-
tiation, we next evaluated potential in vivo effects of miR-146b on M1
macrophage development. First we examined miR-146b expression in
intestinal tissues of IL-10−/− and IL-10R2 mice with colitis. qPCR and
in situ experiments showed that miR-146b expressionwas signiﬁcantly
decreased in the colons of IL-10−/−micewith colitis comparedwithWT
mice (Fig. 7A, B). These results prompted us to design a miR-146b
mimic to test its effectiveness in the control of colitis progress in IL-
10−/− mice. Observations of body weight changed showed no signiﬁ-
cant changes in mice treated with miR-146b mimic, while mice treated
with the scramble continuously lost weight (Fig. 7C). In addition, miR-
146b treated mice exhibited improved intestine morphology (Fig. 7D).
The disease scores were also signiﬁcantly lower for miR-146b mimic
treated mice compared to their scrambles treated counterparts. And
histological study of colon sections from the group mice treated with
scrambles further conﬁrmed the presence of more severe inﬂammatory
cell inﬁltrates, and signiﬁcantly higher pathological scores than those
treated with miR-146b mimic (Fig. 7E,F). qPCR experiments showed
that miR-146b expression was signiﬁcantly increased in the colons of
IL-10−/− mice with mir-146b mimic treatment compared with control
(Fig. 7G). Finally, the percentage of IFN-γ or IL-17 positive CD4+ cells
signiﬁcantly decreased in miR-146b mimic treated mice compared
with the control mice in the mesenteric lymph nodes and the LPLs
(Fig. 7H, Supplementary Fig. 6A). The mice treated with miR-146b had
a signiﬁcantly lower percentage of IL-12 p40- and MHCII expressing
macrophages in colon than the scramble-treated mice (Fig. 7I, Supple-
mentary Fig. 6B). In addition, IRF5 expression was decreased in themu-
cosa of colon with the treatment of miR-146b mimic (Supplementary
Fig. 6C). mRNA expression of M1 macrophages signature molecules
iNOS, IL-12B, IL-6, and TNFα was signiﬁcantly reduced in the colons of
mice treated with miR-146b mimic compared with control (Supple-
mentary Fig. 6D). Furthermore, IL-12 p40, IL-6, and TNFα was signiﬁ-
cantly reduced in the serum of mice treated with miR-146b mimic
compared with control (Supplementary Fig. 6E). We also tested the ef-
fect of miR-146b in an endotoxin shock model. IL-10−/− mice were
injected (i.p.) either with miR-146b mimic or scrambles with
10 mg/kg. 3 h later, mice were then challenged (i.p.) with a lethal
dose of LPS (1000 μg/mouse). Susceptibility and the expression of M1
macrophage signature molecules were monitored. The mice treatedFig. 5.miR-146b deﬁciency enhanced M1 macrophage orientation. WT and Mir146b−/− mic
morphology and HE staining. (B) The presence of Gr+CD11b+ cells in spleen and Bone mar
macrophage genes expression from WT and Mir146b−/− mice. (E) BMDMs from WT and M
analyzed by ﬂow cytometry. Representative FACS dot plots gated on CD11b+ cells and th
supernatants from (E) were collected and the level of IL-6, IL-12 p40, and TNFα secretion in t
WT and Mir146b−/− were treated as before and analyzed via western blot. (H). BMDMs from
and the cells were then stimulated with IFN-γ (20 ng/ml) and LPS (100 ng/ml) for 24 h. The
Representative FACS dot plots gated on CD11b+ cells and the percentage of IL-12/23 p40-pr
collected and the level of IL-6, IL-12 p40, and TNFα production in the supernatants was analyz
was performed for the analysis of IRF5 expression after miR146b mimic treatment in Mir14
were stimulated with IFN-γ (20 ng/ml) and LPS (100 ng/ml) for 24 h in the presence of rIL
**p b 0.01. (L) The whole cell lysates were prepared and western blotting was performed for t
were repeated three times with similar results.with miR-146b mimic were more resistant to endotoxin shock (Fig.
8A). The expression and production of M1macrophage signature mole-
cules including TNFα, IL-12 p40 and others gene were signiﬁcantly
inhibited in mice transferred with the treatment of miR-146b mimic
compared with the control; while the expression of M2 macrophage
signature genes was increased (Fig. 8B, C). Collectively, these results
showed thatmiR-146bmimic is an effective inhibitor ofM1macrophage
activation in vivo and ameliorated colitis development in IL-10−/−
mice.4. Discussion
Interleukin-10 (IL-10) is an important anti-inﬂammatory cytokine
produced by various immune cells and involved in inﬂammatory dis-
eases. However, the contribution of IL-10 to the polarization of macro-
phages and molecular mechanisms behind macrophage polarization
inﬂammation are still not fully understood. In the present study, we
revisited the IL-10 deﬁcientmicewith colitis exhibit enhanced classical-
ly activated macrophage phenotype with high expression of IL-12/23
p40, iNOS, TNFα, IL-6, CXCL9, and IRF5. Interestingly IL-10 and Rag1
double knockoutmice (IL-10−/−/Rag1−/−) spontaneously develop coli-
tis as well with enhanced expression of M1macrophage signature mol-
ecules. We have shown that IL-10 induces miR-146b expression, which
targets IRF5 resulting in the regulation M1 macrophage differentiation
(Curtale et al., 2013). MiR-146b deﬁcient mice exhibit enhanced M1
macrophage polarization. Finally, treatment with miR-146b mimic sig-
niﬁcantly suppressed M1 macrophage polarization in vivo and amelio-
rated colitis development. Collectively, the results suggest IL-10
expressed in M1 macrophages may play an important role in the
reprogramming of M1macrophage differentiation, resulting in the con-
trol of immune responses and pathogenesis of inﬂammatory diseases.
IL-10 is produced by different cell types including T cells, B cells,
mast cells, dendritic cells, and macrophages (Moore et al., 2001). IL-10
has been shown to play an important role in the differentiation and
function of Treg cells, and IL-10 secreted from Treg cells has an essential
role in maintaining homeostasis in the intestinal mucosa (Veenbergen
and Samsom, 2012). Previous studies reported that intestinal macro-
phages can spontaneously produce IL-10 and these macrophages are
believed to be anti-inﬂammatory, as they actively suppress IL-12 and
IL-23 production under non-inﬂammatory conditions (Murai et al.,
2009; Rivollier et al., 2012). In addition, Th17 cells also produce IL-10,
resulting in the modulation of inﬂammatory processes (Zielinski et al.,
2012). It is also known that M2 macrophages produce high amount of
IL-10, which contributes to the anti-inﬂammatory functions of M2mac-
rophages. In the present study, we have demonstrated that IL-10
expressed by M1 macrophages suppresses M1 macrophage activation
in inﬂammation. There are several lines of evidence support this con-
cept. 1). IL-10 and IL-10R2 deﬁcient mice with colitis display an en-
hanced expression of M1 macrophage signature genes including iNOS,
IL-12p40, TNFα, CXCL9, IRF5, etc. 2). The expression of M1 macrophage
signature genes is signiﬁcantly increased in IL-10 and IL-10R2-deﬁcient
M1 macrophages. 3). IL-10−/−/Rag1−/− mice spontaneously develop
intestinal inﬂammation with high expression of M1 macrophagee were raised until 12 weeks of age and mice were sacriﬁced. (A) Photographs of spleen
row cells of WT and Mir146b−/− mice. (C, D) HE staining of colon tissue and qPCR for
ir146b−/− were stimulated with IFN-γ (20 ng/ml) and LPS (100 ng/ml) for 24 h, and
e percentage of IL-12/23 p40-producing CD11b+ cells is shown (**p b 0.01). (F) The
he supernatants was analyzed by ELISA. *p b 0.05. (G) Whole cell lysates of BMDMs from
Mir146b−/− mice were transfected with miR-146b mimic (3 μM) and miR-nc for 48 h
cells were stained for intracellular IL-12/23 p40, NOS2 and analyzed by ﬂow cytometry.
oducing and NOS2-producing CD11b+ cells is shown. (I) The supernatants in (G) were
ed for by ELISA. **p b 0.01. (J) The whole cell lysates were prepared and western blotting
6b−/− mice. β-actin expression serves as a control. (K) BMDMs from Mir146b−/− mice
-10 (10 ng/ml). The supernatants were collected and analyzed for by ELISA. *p b 0.05;
he analysis of IRF5 expression. β-actin expression serves as a control. All the experiments
Fig. 6.Mir146b−/−macrophages induce enhancedCD4+T cell activation. (A) CD4+T cells from spleens and lymphnodes of OTIImicewere prepared and the cellswere incubatedwithWT
orMir146b−/− BMDMs for three days. Representative FACS dot plots gated on CD4+ cells of the percentages of IFN-γ positive CD4+ cells are shown (**p b 0.01). (B) The supernatantswere
analyzed for IFN-γ production by ELISA (**p b 0.01). (C). CD4+ T cells from spleens and lymph nodes of OTII mice were co-cultured as in A and labeled with CFSE. T cell proliferation was
analyzed by ﬂow cytometer. (D). CD4+ T cells from spleens and lymph nodes of OTII mice were prepared and the cells were incubated for three days withMir146b−/− BMDMs already
transfectedwithmiR-146bmimic. Representative FACS dot plots gated on CD4+ cells and the percentages of IFN-γ positive CD4+ cells are shown. (E) The supernatants were analyzed for
IFN-γ production by ELISA. ***p b 0.001. (F) CD4+ T cells from spleens and lymph nodes of OTIImicewere prepared and the cells were incubatedwithWT andMir146b−/− BMDMswhich
were stimulatedwith IFN-γ (20 ng/ml) and LPS (100ng/ml) and rIL-10 for 24 h and analyzed as inD. (G) The supernatantswere analyzed for IFN-γ production by ELISA. **p b 0.001. All the
experiments were repeated three times with similar results.
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10 expressed in M1 macrophages inhibits M1 macrophage differentia-
tion in inﬂammation.
IL-10 induces STAT3 activation in myeloid cells resulting in the reg-
ulation of proinﬂammatory gene expression in these cells, and myeloid
cell speciﬁc deletion of STAT3 develop colitis in a phenomena similar to
IL-10 deﬁcient mice (Kobayashi et al., 2003), suggesting that STAT3 is
key immediate of IL-10 signaling cascade. Interestingly, colitis devel-
oped in myeloid-speciﬁc STAT3 KO mice can be prevented by TLR4 de-
ﬁciency (Kobayashi et al., 2003). In addition, MyD88 deﬁciencycompletely rescues colitis in IL-10 deﬁcient mice (Rakoff-Nahoum et
al., 2006). Recently, Hoshi et al. reported thatMyD88 signaling in colon-
icmononuclear phagocytes drives colitis development in IL-10 deﬁcient
mice (Hoshi et al., 2012). They demonstrated that Villin-MyD88/IL-10
KOmice developed colitis comparable to IL-10 deﬁcientmice. However,
CD11c-MyD88/IL-10 or LysM-MyD88/IL-10 KO mice showed minimal
signs of intestinal inﬂammation. Furthermore, recent reports suggest
IL-10-IL-10R signaling cascade restricted to macrophage is important
for colitis development (Shouval et al., 2014; Zigmond et al., 2014).
Taken together, these observations suggest that IL-10 induced by TLR-
Fig. 7. Treatment with miR-146b mimic suppressed M1 macrophage activation in vivo and ameliorated colitis development. 16-week old WT, IL-10−/−, and IL-10R2−/− mice were
sacriﬁced and colons were removed. (A) Total RNA was extracted from colon tissues and qPCR was performed for the expression of miR-146b. (B) In situ hybridization was performed
for the detection of miR-146b expression in colon tissues in WT and IL-10−/−mice. The data are representative of two independent experiments. (C) 13-week old IL-10−/− mice were
divided into two groups (6 mice/per group). In the treatment group, IL-10−/− mice were treated with miR-146b mimic intraperitoneally twice a week at 10 mg/kg; while in the
control group, mice were treated with miR-146b scramble at same dose for 3 weeks. Body weight was monitored every week and mice were sacriﬁced 3 weeks later. Changes in body
weight of IL-10−/− mice (n = 5 mice per group) treated either with miR146b scramble or mimic were recorded. Data are presented as the mean ± s.d. of the percentage of initial
body weight. (D) Morphology of intestines, (E) sections of colons with colitis, (F) disease scores from IL-10−/− mice three weeks after treated either with 146b mimic or scramble
(n = 5 mice in each group). *p b 0.05. (G) miR146b expression in colon of the scramble and miR146b mimic treatment group (***p b 0.001). (H) The percentages of IL-17- or IFN-γ-
producing cells from intestinal lamina propria lymphocytes of IL-10−/− mice (**p b 0.01). (I) The percentages of IL-12/23 p40-producing and MHCII-expressing cells from intestinal
lamina propria cells of IL-10−/− mice. Representative FACS dot plots gated on F4/80+ cells and the percentage of IL-12/23 p40-producing and MHCII-expressing cells are shown (n =
6), (*p b 0.05; **p b 0.01).
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development.
It is well-known that IL-10 can suppress proinﬂammatory cytokine
gene expressions from different cell types including T cells and macro-
phages; however, the molecular mechanisms for the inhibitory effects
of IL-10 have not been fully deﬁned. Previously, Zhou et al. reported
that IL-10 abolished recruitment of RNA polymerase II to the IL-12/23
p40 promoter in LPS-stimulated macrophages resulted in the suppress-
ing of IL-12/23 p40 gene transcription (Zhou et al., 2004). Driessler et al.
demonstrated that IL-10 selectively induced nuclear translocation andDNA-binding of the repressive NF-κB p50/p50 homodimer is an impor-
tant mechanism for IL-10 to repress inﬂammatory gene transcription
(Driessler et al., 2004). Kabayashi et al. found that acetylated histone
H4 transiently associatedwith the IL-12/23 p40 promoter inWTmacro-
phages, whereas association of these factors was prolonged in IL-10 de-
ﬁcient macrophages (Kobayashi et al., 2012). In addition, experiments
using histone deacetylase inhibitors and HDAC3 short hairpin RNA indi-
cates that HDACs are involved in histone deacetylation of the IL-12/23
p40 promoter by IL-10(Kobayashi et al., 2012). They suggest that his-
tone acetylation on IL-12/23 p40 promoter by HDAC3 mediates
Fig. 8.miR-146bmimic ameliorates endotoxin shock inmice. 7 week old IL-10−/−micewere divided into two group (n= 10/per group) and one group of mice were injected (i.p.) with
miR-146b scramble and the other group ofmicewere injected (i.p.)withmiR-146bmimic at a dose of 10mg/kg. (A) 3 h later both groups ofmicewere challenged (i.p.)with LPS (1000 μg/
per mouse) and the survival of mice was monitored. (B, C) 3 h later both groups of mice were challenged (i.p.) with LPS (300 μg/per mouse) and mice were sacriﬁced 4 h later. Total RNA
was extracted from the spleens ofmice and qPCRwas performed for the analysis ofM1 andM2macrophage signature gene expression. The sera level of IL-6 and TNFαwas determined by
ELISA. *p b 0.05, **p b 0.01.The results were representative of two independent experiments.
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servations indicate that IL-10 may act through diverse mechanisms in
the suppression of proinﬂammatory gene expressions.
Recently, it has been demonstrated that IL-10 can regulate miR ex-
pressions resulting in the anti-inﬂammatory functions. McCoy et al.
have shown that IL-10 suppressed the expression of miR-155 induced
by TLR activation, enhancing the expression of the miR-155 target
gene SH2 domain-containing inositol-5-phosphatase 1 (SHIP1)
(McCoy et al., 2010). In addition, Curtale et al. have demonstrated that
LPS induces expression of miR-146b via an IL-10-dependent and miR-
146bmodulated the TLR4 signaling pathway by direct targeting of mul-
tiple elements, including TLR4,MyD88, IRAK1, and TRAF6 (Curtale et al.,
2013). The enforced expression ofmiR-146b in humanmonocytes leads
to a signiﬁcant reduction in the LPS-dependent production of proin-
ﬂammatory cytokines and chemokines (Curtale et al., 2013). In the
present study,we found thatmiR-146bwas induced inmurineM1mac-
rophages after stimulation with LPS and miR-146b expression was im-
paired in IL-10 deﬁcient cells. Importantly, we demonstrated that
enforced expression of miR-146b signiﬁcantly suppressed M1 macro-
phage differentiation by suppressing M1 macrophage signature gene
expression. In addition, we identiﬁed that the miR-146b targets IRF5, a
key transcription factor for M1 macrophage differentiation. Further-
more, miR-146b deﬁcient mice exhibit enhanced M1 macrophage po-
larization. Thus it may be concluded that IL-10 induces the expressionof miR-146b, which targets IRF5 in the modulation of M1 macrophage
differentiation.
Ourmechanistic studies reveal a key dynamic process that underlies
themodulation of macrophage polarization. As summarized in the Sup-
plementary Fig. 8, our experimental study derives a key time-delayed
incoherent feed-forward control mechanism responsible for the tran-
sient nature of M1 macrophage polarization by LPS. The initial pro-in-
ﬂammatory M1 response to LPS may be due to the rapid activation of
IRF5. The subsequent induction of IL-10, followed by the expression of
miR-146b sets in motion a time-delayed negative attenuation of IRF5.
This delayed negative motif eventually attenuates M1 polarization. By
distilling this key dynamicmotif, we have constructed a skeletal compu-
tational model to re-capture this transient dynamics inmacrophage dif-
ferentiation (Supplementary Fig. 7).
Several techniques have been set up to explore the therapeutic po-
tential of miRs. miRs can be deactivated and silenced by anti-miR oligo-
nucleotides (AMOs), “miR sponges”, and “miRmasking” (McDermott et
al., 2011). Conversely, other treatments simply restore their expression.
This can be achieved through miR mimic or plasmid/viral vector-
encoded miR replacement. miR mimics are small chemically altered
double stranded RNA molecules that imitate endogenous miRs
(McDermott et al., 2011). Plasmid/viral vectors encoding miRs are en-
couraging strategies to replace miRs in vivo, with good transduction ef-
ﬁciency and minimal toxicity (Brown et al., 2006; Colin et al., 2009).
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est in various diseases (Banno et al., 2014; Boon et al., 2013; Ge et al.,
2014; Kornfeld et al., 2013; Sun et al., 2012). In the present study, we
found that miR-146b expression was signiﬁcantly decreased in IL-10
deﬁcient mice with colitis, which prompted us to test miR-146b
mimic in the treatment of colitis in IL-10−/− mice. Interestingly, com-
pared with scrambles, treatment with miR-146b mimic is effective in
amelioration of colitis in IL-10−/− mice maybe through suppressing
M1 macrophage differentiation. The results will suggest targeting
miR-146b can control M1 macrophage activation and ameliorate colitis
development.
Thus, our studies demonstrate that IL-10 dependent miR-146b
expressed in M1 macrophages modulates shaping of macrophage phe-
notype. We suggest a novel mechanism for the effect of miR-146b
targeting IRF5 in the modulation of M1 macrophage differentiation.
TreatmentwithmiR-146bmimic signiﬁcantly improved colitis develop-
ment and clearly suppressed M1 macrophage activation by inhibiting
the expression of M1 macrophage signature genes in vitro and in vivo.
Taken together, the results ﬁrmly establish IL-10 dependent miR-146b
plays an important role in themodulation ofM1macrophage activation
and highlight the potent role of miR-146b in the control of immune re-
sponses and pathogenesis of inﬂammatory diseases.
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